During the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), the GvHD hub was pleased to speak to Zinaida Peric, University of Zagreb, Zagreb, HR. We asked, What do you think are the most promising new drugs in the treatment of steroid-refractory cGvHD?
In this video, Peric discusses the advances in new oral agents, belumosudil and ruxolitinib, for the treatment of steroid-refractory chronic graft-versus-host disease. She also mentions the earlier drug, ibrutinib.
![](https://i.ytimg.com/vi/7H7BiA5He3E/maxresdefault.jpg)